Pre-Made Onfekafusp biosimilar, Whole mAb Fusion: Anti-FN extra domain B therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pre-made Onfekafusp benchmark antibody ( Whole mAb Fusion, anti-FN extra domain B therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-402
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Products Name (INN Index) | Pre-Made Onfekafusp biosimilar, Whole mAb Fusion: Anti-FN extra domain B therapeutic antibody |
---|---|
INN Name | Onfekafusp |
Target | FN extra domain B |
Format | Whole mAb Fusion |
Derivation | NA |
Species Reactivity | Human |
CH1 Isotype | NA |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-III |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2010 |
Year Recommended | 2011 |
Companies | Philogen |
Conditions Approved | NA |
Conditions Active | Malignant melanoma,Basal cell cancer,Squamous cell cancer,Solid tumours |
Conditions Discontinued | NA |
Development Tech | NA |
Previous Name | NA |
Gm Offical Target Name | FN extra domain B |
Package |
Genemeidi Omicron Variant Products
test
Previous slide
Next slide